Dexcom Reports 22% Revenue Growth Amid Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 16 2024
0mins
Should l Buy DXCM?
Source: Business Insider
Dexcom Inc's stock rose 3.01% as it reached a 20-day high, reflecting positive investor sentiment.
The company reported a 22% year-over-year revenue growth to $1.2 billion in Q3 2024, indicating strong market demand despite facing product recall issues. Dexcom's customer base expanded to approximately 2.8 to 2.9 million, with expectations for continued growth in 2025. The limited impact of the recall on overall performance and the introduction of the new Stelo product for non-insulin users further enhance the company's growth prospects.
This strong revenue growth reinforces Dexcom's leadership in the diabetes monitoring market and highlights the significant market potential as many diabetes patients have yet to adopt continuous glucose monitoring technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DXCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DXCM
Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 67.790
Low
68.00
Averages
82.54
High
100.00
Current: 67.790
Low
68.00
Averages
82.54
High
100.00
About DXCM
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dexcom CGM Enhances Long-Term Health for Diabetes Patients
- Long-Term Health Improvement: New registry study data indicates that long-term use of Dexcom G7 significantly lowers A1C levels and aids weight management for non-insulin-treated Type 2 diabetes patients, reinforcing the need to broaden CGM access to enhance overall health outcomes for diabetes patients.
- Reduced Hospitalization Rates: The use of Dexcom CGM is associated with significant reductions in diabetic ketoacidosis (DKA)-related hospitalizations and emergency room visits, demonstrating the effectiveness of real-time glucose monitoring and alert systems in both children and adults, thereby solidifying Dexcom's critical role in diabetes management.
- Education and Training Framework: At the upcoming ATTD conference, Dexcom will introduce the first consensus-based CGM competency framework aimed at providing healthcare professionals with a clear training structure, which will enhance the quality and consistency of CGM support and advance industry education.
- Commitment to Product Innovation: Dexcom will showcase its product roadmap at ATTD, emphasizing its ongoing innovation in diabetes care and health sectors, particularly with the upcoming Dexcom G7 and the Dexcom Academy education platform, aimed at raising the standard of diabetes management globally.
See More
Dexcom G7 Enhances Diabetes Management and Health Outcomes
- Long-Term Benefits: New registry study data indicates that long-term use of Dexcom G7 significantly aids weight management and lowers A1C levels for Type 2 diabetes patients not on insulin therapy, reinforcing the need to broaden CGM access beyond insulin-treated populations, thereby enhancing overall patient health outcomes.
- Clinical Evidence Showcase: Dexcom will present multiple clinical and real-world evidence at the 2026 ATTD conference in Barcelona, demonstrating the health benefits of its CGM technology for all diabetes types, further solidifying its leadership position in diabetes management.
- Commitment to Education and Innovation: Dexcom is launching the Dexcom Academy education platform aimed at enhancing healthcare professionals' CGM support capabilities through a structured training framework, with plans for rollout in several countries, thereby increasing the professionalism of global diabetes care.
- Product Roadmap: At the ATTD conference, Dexcom will unveil upcoming product features, including Dexcom G7 and Dexcom ONE+, showcasing its ongoing innovation in diabetes management and health, further driving CGM education and product advancements.
See More
Intuitive Surgical and DexCom: Future Prospects Analysis
- Challenges for Intuitive Surgical: Intuitive Surgical has faced tariffs and competition from Medtronic's new Hugo system, resulting in a 13% stock price decline over the past year; however, it is expected to benefit from the growing surgical demand due to an aging population over the next decade, maintaining its market leadership.
- Market Potential: By 2034, the U.S. population aged 65 and older is projected to exceed those aged 18 and under, which will drive demand for Intuitive Surgical's da Vinci system, allowing for revenue and earnings growth despite competitive pressures due to its high switching costs and innovative capabilities.
- DexCom's Market Opportunities: DexCom's leadership in the CGM market remains intact despite last year's minor product recalls, with potential to expand its market share by targeting over 9 million insured diabetes patients who are not currently using CGM technology.
- New Product Development: DexCom's new product Stelo has attracted over 500,000 users in the U.S., targeting the large market of over 40% of the population with prediabetes, indicating significant growth potential in the non-diabetic patient segment, which is expected to drive future company growth.
See More
Intuitive Surgical and DexCom's Growth Prospects Amid Challenges
- Growing Market Demand: Intuitive Surgical faces tariffs and competitive pressures in 2025, yet its leadership in the robotic-assisted surgery market and the aging population trend are expected to drive demand growth over the next decade, with projections indicating that by 2034, the U.S. population aged 65 and older will surpass those under 18, enhancing its market potential.
- Competitive Pressure Management: Despite Medtronic's Hugo system gaining competitive clearance in the U.S., Intuitive Surgical can leverage its high switching costs and innovative capabilities to mitigate tariff impacts, with its installed base of 11,106 da Vinci devices poised to generate significant revenue growth.
- DexCom's Market Opportunities: DexCom's continuous glucose monitoring devices have substantial market potential among diabetes patients, as last year's product recalls affected only a small number of users, with over 9 million patients in the U.S. having insurance coverage but not utilizing the technology, indicating strong growth prospects.
- Attractive New Products: The launch of DexCom's Stelo product, which received clearance in 2024 and attracted over 500,000 users, targets the over 40% of the U.S. population with prediabetes, further expanding its market share and expected to drive future growth for the company.
See More
Investigation into DexCom Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of DexCom may seek corporate governance reforms, return of funds, or court-approved financial awards, thereby enhancing their legal standing and rights protection.
- Importance of Participation: Shareholder involvement can improve company policies, practices, and oversight mechanisms, promoting transparency and accountability, which can enhance management efficiency and shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
DexCom Positioned to Benefit from GLP-1 Drug Boom
- Market Opportunity: DexCom estimates over 9 million patients in the U.S. have reimbursement for CGM devices but have yet to adopt them, indicating a massive growth potential that could be further driven by the rise of GLP-1 drugs, thereby boosting the company's revenue.
- Complementary Relationship: Studies show that using CGM devices alongside GLP-1 medications significantly improves health outcomes for diabetes patients, allowing DexCom to benefit from the popularity of GLP-1 drugs without needing to develop new therapies, creating a win-win situation.
- Innovation-Driven Growth: DexCom's continuous innovations and market expansions have historically led to solid financial results, and the company is expected to continue benefiting from the growth trends associated with GLP-1 drugs as it secures reimbursement for more patients in various countries.
- Investment Appeal: Given DexCom's market potential and ongoing innovations, investing $10,000 in its shares today is considered a wise move, especially as the company stands to profit from the GLP-1 drug boom.
See More
Dexcom CGM Enhances Long-Term Health for Diabetes Patients
- Long-Term Health Improvement: New registry study data indicates that long-term use of Dexcom G7 significantly lowers A1C levels and aids weight management for non-insulin-treated Type 2 diabetes patients, reinforcing the need to broaden CGM access to enhance overall health outcomes for diabetes patients.
- Reduced Hospitalization Rates: The use of Dexcom CGM is associated with significant reductions in diabetic ketoacidosis (DKA)-related hospitalizations and emergency room visits, demonstrating the effectiveness of real-time glucose monitoring and alert systems in both children and adults, thereby solidifying Dexcom's critical role in diabetes management.
- Education and Training Framework: At the upcoming ATTD conference, Dexcom will introduce the first consensus-based CGM competency framework aimed at providing healthcare professionals with a clear training structure, which will enhance the quality and consistency of CGM support and advance industry education.
- Commitment to Product Innovation: Dexcom will showcase its product roadmap at ATTD, emphasizing its ongoing innovation in diabetes care and health sectors, particularly with the upcoming Dexcom G7 and the Dexcom Academy education platform, aimed at raising the standard of diabetes management globally.
See More
Dexcom G7 Enhances Diabetes Management and Health Outcomes
- Long-Term Benefits: New registry study data indicates that long-term use of Dexcom G7 significantly aids weight management and lowers A1C levels for Type 2 diabetes patients not on insulin therapy, reinforcing the need to broaden CGM access beyond insulin-treated populations, thereby enhancing overall patient health outcomes.
- Clinical Evidence Showcase: Dexcom will present multiple clinical and real-world evidence at the 2026 ATTD conference in Barcelona, demonstrating the health benefits of its CGM technology for all diabetes types, further solidifying its leadership position in diabetes management.
- Commitment to Education and Innovation: Dexcom is launching the Dexcom Academy education platform aimed at enhancing healthcare professionals' CGM support capabilities through a structured training framework, with plans for rollout in several countries, thereby increasing the professionalism of global diabetes care.
- Product Roadmap: At the ATTD conference, Dexcom will unveil upcoming product features, including Dexcom G7 and Dexcom ONE+, showcasing its ongoing innovation in diabetes management and health, further driving CGM education and product advancements.
See More
Intuitive Surgical and DexCom: Future Prospects Analysis
- Challenges for Intuitive Surgical: Intuitive Surgical has faced tariffs and competition from Medtronic's new Hugo system, resulting in a 13% stock price decline over the past year; however, it is expected to benefit from the growing surgical demand due to an aging population over the next decade, maintaining its market leadership.
- Market Potential: By 2034, the U.S. population aged 65 and older is projected to exceed those aged 18 and under, which will drive demand for Intuitive Surgical's da Vinci system, allowing for revenue and earnings growth despite competitive pressures due to its high switching costs and innovative capabilities.
- DexCom's Market Opportunities: DexCom's leadership in the CGM market remains intact despite last year's minor product recalls, with potential to expand its market share by targeting over 9 million insured diabetes patients who are not currently using CGM technology.
- New Product Development: DexCom's new product Stelo has attracted over 500,000 users in the U.S., targeting the large market of over 40% of the population with prediabetes, indicating significant growth potential in the non-diabetic patient segment, which is expected to drive future company growth.
See More
Intuitive Surgical and DexCom's Growth Prospects Amid Challenges
- Growing Market Demand: Intuitive Surgical faces tariffs and competitive pressures in 2025, yet its leadership in the robotic-assisted surgery market and the aging population trend are expected to drive demand growth over the next decade, with projections indicating that by 2034, the U.S. population aged 65 and older will surpass those under 18, enhancing its market potential.
- Competitive Pressure Management: Despite Medtronic's Hugo system gaining competitive clearance in the U.S., Intuitive Surgical can leverage its high switching costs and innovative capabilities to mitigate tariff impacts, with its installed base of 11,106 da Vinci devices poised to generate significant revenue growth.
- DexCom's Market Opportunities: DexCom's continuous glucose monitoring devices have substantial market potential among diabetes patients, as last year's product recalls affected only a small number of users, with over 9 million patients in the U.S. having insurance coverage but not utilizing the technology, indicating strong growth prospects.
- Attractive New Products: The launch of DexCom's Stelo product, which received clearance in 2024 and attracted over 500,000 users, targets the over 40% of the U.S. population with prediabetes, further expanding its market share and expected to drive future growth for the company.
See More
Investigation into DexCom Officers' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of DexCom, Inc. breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Legal Relief Options: Long-term shareholders of DexCom may seek corporate governance reforms, return of funds, or court-approved financial awards, thereby enhancing their legal standing and rights protection.
- Importance of Participation: Shareholder involvement can improve company policies, practices, and oversight mechanisms, promoting transparency and accountability, which can enhance management efficiency and shareholder value.
- Global Investor Representation: Halper Sadeh LLC represents investors worldwide, focusing on combating securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors.
See More
DexCom Positioned to Benefit from GLP-1 Drug Boom
- Market Opportunity: DexCom estimates over 9 million patients in the U.S. have reimbursement for CGM devices but have yet to adopt them, indicating a massive growth potential that could be further driven by the rise of GLP-1 drugs, thereby boosting the company's revenue.
- Complementary Relationship: Studies show that using CGM devices alongside GLP-1 medications significantly improves health outcomes for diabetes patients, allowing DexCom to benefit from the popularity of GLP-1 drugs without needing to develop new therapies, creating a win-win situation.
- Innovation-Driven Growth: DexCom's continuous innovations and market expansions have historically led to solid financial results, and the company is expected to continue benefiting from the growth trends associated with GLP-1 drugs as it secures reimbursement for more patients in various countries.
- Investment Appeal: Given DexCom's market potential and ongoing innovations, investing $10,000 in its shares today is considered a wise move, especially as the company stands to profit from the GLP-1 drug boom.
See More
